The domestic supply of the ADHD (Attention-Deficit·Hyperactivity Disorder) treatment ‘Strattera (atomoxetine) was completely discontinued in Korea. Its supplier Lilly Korea said, “We have currently discontinued its supply, with no plans for resupply.

According to the pharmaceutical industry on the 17th, Lilly Korea recently notified Boryeong Pharmaceutical that it will suspend the supply of Strattera. Lilly Korea has been supplying Strattera to the domestic market through Boryeong.

Lilly Korea had notified Boryung about the discontinuation earlier this year and additionally announced that it has no plans to resupply Strattera in Korea. “Supply of Straterra will be discontinued not on